His primary areas of study are Psychiatry, Internal medicine, Depression, Major depressive disorder and Placebo. Richard C. Shelton has included themes like Case-control study and Pediatrics in his Psychiatry study. His Internal medicine research incorporates themes from Venlafaxine and Endocrinology.
His studies deal with areas such as Functional magnetic resonance imaging and Clinical psychology as well as Depression. His work carried out in the field of Major depressive disorder brings together such families of science as Antidepressant, Adverse effect, Clinical trial and Young adult. The study incorporates disciplines such as Response rate and Mood in addition to Placebo.
The scientist’s investigation covers issues in Psychiatry, Internal medicine, Depression, Major depressive disorder and Placebo. He interconnects Endocrinology and Rating scale in the investigation of issues within Internal medicine. As a part of the same scientific family, Richard C. Shelton mostly works in the field of Depression, focusing on Clinical psychology and, on occasion, Psychotherapist.
In the field of Major depressive disorder, his study on Hamilton Rating Scale for Depression overlaps with subjects such as Pimavanserin. His study in Placebo is interdisciplinary in nature, drawing from both Escitalopram, Anesthesia and Ziprasidone. His research in Cognitive therapy tackles topics such as Cognitive behavioral therapy which are related to areas like Combined Modality Therapy.
His main research concerns Internal medicine, Depression, Major depressive disorder, Psychiatry and Randomized controlled trial. His research integrates issues of Placebo, Endocrinology and Rating scale in his study of Internal medicine. His Depression study incorporates themes from Body mass index and Ketamine.
In Major depressive disorder, Richard C. Shelton works on issues like Antidepressant, which are connected to Pharmacology and Cognitive therapy. His study in the fields of Pharmacotherapy under the domain of Psychiatry overlaps with other disciplines such as Weight gain. His Randomized controlled trial study deals with Number needed to treat intersecting with Combined Modality Therapy, Cognitive behavioral therapy and Psychological intervention.
Richard C. Shelton mostly deals with Internal medicine, Major depressive disorder, Depression, Randomized controlled trial and Bipolar disorder. Richard C. Shelton has researched Internal medicine in several fields, including Endocrinology and Mood disorders. His Major depressive disorder study combines topics in areas such as Placebo-controlled study, microRNA, Reuptake inhibitor and Immunology.
Richard C. Shelton combines subjects such as Body mass index, Ketamine and Rating scale with his study of Depression. The Randomized controlled trial study combines topics in areas such as Young adult, Relapse prevention and Placebo, Number needed to treat. Quetiapine is a primary field of his research addressed under Psychiatry.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Jay C. Fournier;Robert J. DeRubeis;Steven D. Hollon;Sona Dimidjian.
Cognitive therapy vs medications in the treatment of moderate to severe depression.
Robert J. DeRubeis;Steven D. Hollon;Jay D. Amsterdam;Richard C. Shelton.
Archives of General Psychiatry (2005)
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.
Steven D. Hollon;Robert J. DeRubeis;Richard C. Shelton;Jay D. Amsterdam.
Archives of General Psychiatry (2005)
A novel augmentation strategy for treating resistant major depression.
Richard C. Shelton;Gary D. Tollefson;Mauricio Tohen;Stephen Stahl.
American Journal of Psychiatry (2001)
Effectiveness of St John's wort in major depression: A randomized controlled trial
Richard C. Shelton;Martin B. Keller;Allan Gelenberg;David L. Dunner.
Effort-Based Decision-Making in Major Depressive Disorder: A Translational Model of Motivational Anhedonia
Michael T. Treadway;Nicholas A. Bossaller;Richard C. Shelton;David H. Zald.
Journal of Abnormal Psychology (2012)
Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression
R C Shelton;J Claiborne;M Sidoryk-Wegrzynowicz;R Reddy.
Molecular Psychiatry (2011)
Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.
Heath D Schmidt;Richard C Shelton;Ronald S Duman.
Cognitive therapy and pharmacotherapy for depression.
Steven D. Hollon;Richard C. Shelton;Peter T. Loosen.
Journal of Consulting and Clinical Psychology (1991)
Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study
A. John Rush;Madhukar H. Trivedi;Jonathan W. Stewart;Andrew A. Nierenberg.
American Journal of Psychiatry (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: